NCT07013370View on ClinicalTrials.gov

Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

RecruitingOBSERVATIONAL

Enrollment

150

Participants

Timeline

Start Date

June 2, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

June 2, 2026

Conditions

Immunoglobulin ProphylaxisCytomegalovirus InfectionsAllogeneic Hematopoietic Stem Cell TransplantationTransplant-Related Disorder

Interventions

BIOLOGICAL

Anti-CMV immunoglobulins [Megalotect (R)]

Children received an anti-CMV immunoglobulin to prevent viral infections

Trial Locations (1)

34137

RECRUITING

IRCCS Burlo Garofolo, Trieste

All Listed Sponsors

collaborator

IRCCS Burlo Garofolo

OTHER

lead

Antonello Di Paolo, M.D., Ph.D.

OTHER

NCT07013370 - Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter